MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.31 2.34

Buy Sell

Overview

Share price change

24h

Current

Min

1.28

Max

1.31

Key metrics
By Trading Economics
Income	17M -26M
Employees	171
EBITDA	19M -23M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+125.56% upside

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-21M 82M
Previous open	-1.03
Previous close	1.31

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sty 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 sty 2026, 00:00 UTC

Earnings

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 sty 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 sty 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 sty 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 sty 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 sty 2026, 22:56 UTC

Acquisitions, Mergers, Takeovers

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 sty 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 sty 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14 sty 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 sty 2026, 22:09 UTC

Earnings

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 sty 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 sty 2026, 22:08 UTC

Earnings

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 sty 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 sty 2026, 21:53 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 sty 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Announces Positive Profit Alert for 2025

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Citigroup Acting as Financial Advisor to WuXi XDC

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 sty 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 sty 2026, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

14 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 sty 2026, 21:49 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 sty 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 sty 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

WuXi XDC Makes Cash Offer for BioDlink International

14 sty 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 sty 2026, 20:30 UTC

Market Talk

Earnings

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 sty 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 sty 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 sty 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 sty 2026, 19:06 UTC

Market Talk

Earnings

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

125.56% upside

12 Months Forecast

Average 3 USD 125.56%

High 4 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.